A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.
about
Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growthHIF prolyl hydroxylase inhibitors for anemiaLong term effect of curcumin in regulation of glycolytic pathway and angiogenesis via modulation of stress activated genes in prevention of cancerRoles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.Targeting the tumor microenvironment: focus on angiogenesis.PGC-1-related coactivator (PRC), a sensor of metabolic stress, orchestrates a redox-sensitive program of inflammatory gene expression.Recent progress in targeting cancer.Myeloma as a model for the process of metastasis: implications for therapyEmerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy.Malate dehydrogenase-2 inhibitor LW6 promotes metabolic adaptations and reduces proliferation and apoptosis in activated human T-cells.The "Sharp" blade against HIF-mediated metastasis.PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Methylglyoxal suppresses human colon cancer cell lines and tumor growth in a mouse model by impairing glycolytic metabolism of cancer cells associated with down-regulation of c-Myc expression.Regulation of CDKN2B expression by interaction of Arnt with Miz-1--a basis for functional integration between the HIF and Myc gene regulatory pathways.Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism.Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer.Progress of molecular targeted therapies for advanced renal cell carcinoma.A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity.Targeting the Bone Marrow Microenvironment.Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma.SEPT9_i1 is required for the association between HIF-1α and importin-α to promote efficient nuclear translocation.miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cellsExclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancerTranscriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.miR-196b targets c-myc and Bcl-2 expression, inhibits proliferation and induces apoptosis in endometriotic stromal cells.Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium.Tenascin-C, GLUT-1, and syndecan-2 expression in juvenile nasopharyngeal angiofibroma: correlations to vessel density and tumor stage.LncRNA IDH1-AS1 links the functions of c-Myc and HIF1α via IDH1 to regulate the Warburg effect.Pleiotrophin is a potential colorectal cancer prognostic factor that promotes VEGF expression and induces angiogenesis in colorectal cancer.Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent.Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB.
P2860
Q24603549-BD01F384-5C4D-47B8-93D3-84BC847E9861Q28307377-11696723-C1C9-4F01-A838-35C802A00928Q33763348-C9754FF1-B156-4156-82AC-DD1CB7E3EE97Q34966603-0C014623-F210-4E2A-94F9-CB482BB1C62EQ35108007-9E0715D1-E3CF-4E38-9D3C-92E3D580584BQ35184806-F5C32CFA-2FE6-4B91-981E-DA9AEEE91A4DQ35562841-B1A36191-F013-4238-B506-4BAE092630E5Q35740782-8534EC79-E697-43B6-93E8-90025F5B9AAFQ36079800-7B0B4A2C-4187-4A73-8719-09CF28D2B3DAQ36111593-E09F8B9A-B3B5-44A2-B7C4-F0F33C7B7019Q36334286-C0E0DA29-34B7-48EB-9623-06FEB6CFFC99Q36581657-527D1C52-9044-485F-8A89-E5D8C9A7C257Q36839558-DC03FD1F-DA71-49E1-9C1C-7A7A91FDC417Q36862768-5082999B-8AF2-4A44-BD37-005137780959Q37283010-3A3B358C-7BE4-4AAD-A790-F8069718CE54Q37699714-4F333EE6-F45A-475D-B6E9-44261D088402Q37706550-EF76958F-B742-4135-BA4F-FC74A2446746Q38056889-6E38EF91-4CED-4DA9-A2D6-64A8445D6CD5Q38125169-A3B4764E-1219-4BC6-A357-4FE06289A6D5Q38149133-EFB4BD16-8521-428D-94F1-6731AECAF551Q38800369-69DE6268-54C6-409D-8C05-D55A7FF9FB14Q38970585-3879B98A-74A1-4EFB-AF11-D52E1AD98BC9Q39004271-107DAA90-FDE5-4A28-B1A9-E90DF843FE5CQ39091873-ED6D598F-618D-4EC9-9B17-D43139DF259DQ41894298-08F799A1-56F9-4F46-B73C-D5523025ACE0Q41983615-F68BFE16-DC38-4F9B-96A5-3A04A52FB029Q44004521-D15C34EE-B4AE-4DDC-8891-7FF061F69B6EQ44536293-B0E2E289-0271-45ED-A523-4F4A88729933Q45120893-5BE43061-C85A-4F73-8B16-9BF5A1E92D7BQ46314271-04388298-680F-414A-9B47-78E0427743BCQ48147678-27903404-ABCC-4CBA-9F4A-56E214E4DB0BQ51848175-5A5B5D08-E7BA-4312-81B4-D01D20632EB6Q54309194-35F6393A-54D1-4A11-9530-1BE74D798F72Q54858561-EEE32CAC-F635-45E9-BC9F-E9BEB071CE65
P2860
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.
@ast
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.
@en
type
label
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.
@ast
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.
@en
prefLabel
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.
@ast
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.
@en
P2860
P356
P1433
P1476
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.
@en
P2093
Kenneth C Anderson
Klaus Podar
P2860
P304
P356
10.4161/CC.9.9.11358
P577
2010-05-01T00:00:00Z